DHMRI’s In Vitro Sciences (IVTS) Laboratory analyzed whole blood samples as part of a Phase II Clinical Trial that found a previously unknown biomarker of effectiveness for the drug Abatacept (CTLA‐4 lg).
IVTS used cell surface and intracellular assays on a multi‐color Flow Cytometry platform to analyze the blood samples of over 100 patients collected over a three year period. The result was the identification of Central Memory CD4 positive cells as a marker of the effectiveness of the drug Abatacept to treat type 1 diabetes. Abatacept is more commonly used for the treatment of rheumatoid arthritis.
“This study is one example of how we can assist organizations with clinical trials, and how useful our expertise in multi‐color flow cytometry is,” said Qi Jiang, MD, PhD, IVTS Group Leader. “We also provide our collaborators with in depth data analysis that makes the difference in identifying new biomarkers.”
TrialNet, a network of US and international clinical centers advancing the study, prevention, and early treatment of type 1 diabetes, conducted the clinical Phase II trial.
The results of the study were originally published online in May 2014 in the journal Diabetes.